These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 29697277)
21. Distinct Biomarkers for Early Diagnosis of Diabetic Nephropathy. Kishore L; Kaur N; Singh R Curr Diabetes Rev; 2017; 13(6):598-605. PubMed ID: 27924722 [TBL] [Abstract][Full Text] [Related]
22. Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. Rotbain Curovic V; Hansen TW; Eickhoff MK; von Scholten BJ; Reinhard H; Jacobsen PK; Persson F; Parving HH; Rossing P Acta Diabetol; 2018 Nov; 55(11):1143-1150. PubMed ID: 30105469 [TBL] [Abstract][Full Text] [Related]
23. Urinary podocalyxin levels were associated with urinary albumin levels among patients with diabetes. Shoji M; Kobayashi K; Takemoto M; Sato Y; Yokote K Biomarkers; 2016; 21(2):164-7. PubMed ID: 26635084 [TBL] [Abstract][Full Text] [Related]
24. Study of protein profiling of human urine in diabetic hypertensive nephropathy versus normal healthy controls. Butt A; Riaz S Diabetes Technol Ther; 2010 May; 12(5):379-86. PubMed ID: 20388048 [TBL] [Abstract][Full Text] [Related]
25. Association of ApoE gene with type 2 diabetic nephropathy in a Chinese population: a meta-analysis of case-control studies. Zhang C; Li S; Zhang X; Liu H; Luo Y Ann Endocrinol (Paris); 2015 Oct; 76(5):601-13. PubMed ID: 25669588 [TBL] [Abstract][Full Text] [Related]
26. Associations between urinary kidney injury biomarkers and cardiovascular mortality risk in elderly men with diabetes. Tonkonogi A; Carlsson AC; Helmersson-Karlqvist J; Larsson A; Ärnlöv J Ups J Med Sci; 2016 Aug; 121(3):174-8. PubMed ID: 27321055 [TBL] [Abstract][Full Text] [Related]
27. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. Kim SS; Song SH; Kim IJ; Yang JY; Lee JG; Kwak IS; Kim YK Diabetes Res Clin Pract; 2012 Aug; 97(2):251-7. PubMed ID: 22440044 [TBL] [Abstract][Full Text] [Related]
28. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547 [TBL] [Abstract][Full Text] [Related]
29. Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy. Suzuki K; Babazono T; Murata H; Iwamoto Y Diabetes Care; 2005 Aug; 28(8):2038-9. PubMed ID: 16043754 [No Abstract] [Full Text] [Related]
30. Heme oxygenase-1 in type 2 diabetes: from cell first-line defense to early marker of diabetic nephropathy. Pagnin E; Maiolino G; Calò LA Minerva Med; 2016 Apr; 107(2):123-4. PubMed ID: 27064585 [No Abstract] [Full Text] [Related]
31. Relationship between methylenetetrahydrofolate reductase (MTHFR) A1298C gene polymorphism and type 2 diabetic nephropathy risk: a meta-analysis. Zhang J; Xiao Y; Zhang XW; Gao ZQ; Han JH Ren Fail; 2014 Jul; 36(6):974-8. PubMed ID: 24678913 [TBL] [Abstract][Full Text] [Related]
32. Urinary platelet-derived growth factor-BB as an early marker of nephropathy in patients with type 2 diabetes: an Egyptian study. Bessa SS; Hussein TA; Morad MA; Amer AM Ren Fail; 2012; 34(6):670-5. PubMed ID: 22486214 [TBL] [Abstract][Full Text] [Related]
33. Urinary exosomal microRNA panel unravels novel biomarkers for diagnosis of type 2 diabetic kidney disease. Eissa S; Matboli M; Aboushahba R; Bekhet MM; Soliman Y J Diabetes Complications; 2016; 30(8):1585-1592. PubMed ID: 27475263 [TBL] [Abstract][Full Text] [Related]
34. Early urinary and plasma biomarkers for experimental diabetic nephropathy. Alter ML; Kretschmer A; Von Websky K; Tsuprykov O; Reichetzeder C; Simon A; Stasch JP; Hocher B Clin Lab; 2012; 58(7-8):659-71. PubMed ID: 22997966 [TBL] [Abstract][Full Text] [Related]
35. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Rossing K; Mischak H; Parving HH; Christensen PK; Walden M; Hillmann M; Kaiser T Kidney Int; 2005 Jul; 68(1):193-205. PubMed ID: 15954909 [TBL] [Abstract][Full Text] [Related]
36. Discovery and verification of urinary peptides in type 2 diabetes mellitus with kidney injury. Fu G; Du Y; Chu L; Zhang M Exp Biol Med (Maywood); 2016 Jun; 241(11):1186-94. PubMed ID: 26846977 [TBL] [Abstract][Full Text] [Related]
37. Relationship between PPARγ Pro12Ala gene polymorphism and type 2 diabetic nephropathy risk in Asian population: results from a meta-analysis. Liu G; Zhou TB; Jiang Z; Zheng D; Yuan F; Li Y; Hu H; Chen Z J Recept Signal Transduct Res; 2014 Apr; 34(2):131-6. PubMed ID: 24303936 [TBL] [Abstract][Full Text] [Related]
38. Role of mindin in diabetic nephropathy. Murakoshi M; Gohda T; Tanimoto M; Funabiki K; Horikoshi S; Tomino Y Exp Diabetes Res; 2011; 2011():486305. PubMed ID: 22235198 [TBL] [Abstract][Full Text] [Related]
39. Urinary and Blood MicroRNA-126 and -770 are Potential Noninvasive Biomarker Candidates for Diabetic Nephropathy: a Meta-Analysis. Park S; Moon S; Lee K; Park IB; Lee DH; Nam S Cell Physiol Biochem; 2018; 46(4):1331-1340. PubMed ID: 29689545 [TBL] [Abstract][Full Text] [Related]
40. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Koshimura J; Fujita H; Narita T; Shimotomai T; Hosoba M; Yoshioka N; Kakei M; Fujishima H; Ito S Biochem Biophys Res Commun; 2004 Mar; 316(1):165-9. PubMed ID: 15003525 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]